Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC
April 3rd 2017
Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.